MARKET

ACER

ACER

Acer Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.120
-0.080
-3.64%
Closed 16:00 01/21 EST
OPEN
2.120
PREV CLOSE
2.200
HIGH
2.190
LOW
2.120
VOLUME
23.13K
TURNOVER
--
52 WEEK HIGH
5.39
52 WEEK LOW
1.680
MARKET CAP
30.34M
P/E (TTM)
-1.6714
1D
5D
1M
3M
1Y
5Y
Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?
Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
Zacks · 01/13 14:40
We're Interested To See How Acer Therapeutics (NASDAQ:ACER) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 01/07 09:29
BRIEF-Acer Therapeutics Got Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
reuters.com · 12/30/2021 21:34
Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences
NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unme...
GlobeNewswire · 12/22/2021 13:30
Acer Therapeutics wins FDA nod for hot flashes trial
Acer Therapeutics (NASDAQ:ACER) has gained ~3.3% in the pre-market after announcing the FDA clearance of its Investigational New Drug (IND) application for ACER-801 (osanetant) as a treatment for induced Vasomotor
Seekingalpha · 12/09/2021 14:21
Acer Therapeutics Announces ACER-801 IND Clearance For The Treatment Of Induced Vasomotor Symptoms
Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical
Benzinga · 12/09/2021 13:33
BRIEF-Acer Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
reuters.com · 11/24/2021 21:05
5 Stocks To Watch For November 22, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Agilent Technologies, Inc. (NYSE: A) to report quarterly earnings at $1.03 per share on revenue of $1.45 billion before the opening bell. Agilent shares rose 0.4% to $164.90 in ...
Benzinga · 11/22/2021 08:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACER. Analyze the recent business situations of Acer Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACER stock price target is 11.00 with a high estimate of 12.00 and a low estimate of 10.00.
High12.00
Average11.00
Low10.00
Current 2.120
EPS
Actual
Estimate
-0.40-0.30-0.20-0.10
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 50
Institutional Holdings: 1.74M
% Owned: 12.17%
Shares Outstanding: 14.31M
TypeInstitutionsShares
Increased
5
12.13K
New
2
36.68K
Decreased
6
32.37K
Sold Out
7
53.37K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Aselage
President/Chief Executive Officer/Director
Christopher Schelling
Chief Financial Officer/Chief Operating Officer
Harry Palmin
Other
Jefferson Davis
Other
John Klopp
Other
Matthew Seibt
Secretary
Donald Joseph
Independent Director
Jason Amello
Independent Director
John Dunn
Independent Director
Michelle Griffin
No Data
About ACER
Acer Therapeutics Inc. is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The Company's pipeline includes four programs: ACER-001, EDSIVO, ACER-801 and ACER-2820. The ACER-001 (Sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). The EDSIVO (celiprolol) is a selective adrenergic modulator (SAM) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. The ACER-801 (osanetant) is a non-peptide tachykinin NK3 receptor antagonist for the treatment of induced Vasomotor Symptoms (iVMS). The ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.

Webull offers kinds of Acer Therapeutics Inc stock information, including NASDAQ:ACER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACER stock methods without spending real money on the virtual paper trading platform.